The Complete Guide to Choosing the Right IRB Path for Your Study

Progress in healthcare research and innovation should not be slowed by uncertainty around Institutional Review Board (IRB) procedures.

For clinicians, nurse leaders, and independent researchers, one of the biggest early challenges is determining the right IRB pathway for a study and securing a timely, compliant review.

Selecting the right IRB path is one of the most important first decisions you make. Choosing the wrong route can lead to unnecessary delays, higher costs, added administrative burden, or even a stalled project.

This guide explains the main IRB pathways, when each one applies, and how to confidently choose the best fit for your study. New to Rapid IRB? Start with our overview of what Rapid IRB is and how the platform works.

Why the Right IRB Pathway Matters

Institutional Review Boards exist to protect human subjects and help ensure ethical research practices. In the United States, IRB oversight is governed by federal regulations under the Common Rule, 45 CFR 46.

Not every study requires the same level of review. Identifying the correct pathway early can help you:

• Avoid delays in project launch
• Reduce unnecessary costs
• Stay compliant with federal and institutional requirements
• Maintain momentum for innovation, publication, and implementation

The Three Primary IRB Pathways

1. Exempt Review

Best for: Low-risk research involving minimal interaction or the use of existing, low-risk data.

Exempt studies still require an initial determination, but they are exempt from ongoing IRB oversight because they fall within specific regulatory exemption categories under 45 CFR 46.104.

Common examples include:

• Anonymous surveys or interviews
• Educational research
• Retrospective chart reviews with de-identified data
• Some low-risk quality improvement projects

Key advantage: Exempt review is typically the fastest pathway and carries the lowest administrative burden.

Key consideration: Exempt status cannot be self-determined. It must be confirmed by a qualified reviewing body.

2. Expedited Review

Best for: Minimal risk studies that do not qualify as exempt.

Expedited review applies to research involving no more than minimal risk, but where the study includes identifiable data, interaction with participants, or procedures that do not fit exemption criteria.

Examples include:

• Studies collecting identifiable health data
• Blood sample collection within permitted limits
• Behavioral interventions without significant risk

These studies are reviewed by a designated IRB member rather than the convened full board.

Key advantage: Expedited review is faster than full board review while allowing for more complex study designs.

Key consideration: A formal submission and supporting documentation are still required.

3. Full Board Review

Best for: Studies involving greater than minimal risk.

Full board review is required when research involves more complex ethical, clinical, or legal considerations, including studies that:

• Involve vulnerable populations, such as prisoners or certain pediatric groups
• Include invasive procedures or higher-risk interventions
• Present potential physical, psychological, social, or legal risk

These studies are reviewed during a convened IRB meeting.

Key advantage: This is the appropriate pathway for higher-risk and more complex research.

Key consideration: Full board review usually involves the longest timeline and the greatest administrative burden.

Choosing the Right IRB Path. Where Most Researchers Get Stuck

On paper, choosing the correct IRB pathway can seem straightforward. In practice, this is where many studies lose momentum.

Researchers often ask:

• Is this research or quality improvement?
• Does this study qualify as exempt, or am I overlooking something?
• Should I just submit to the full IRB to be safe?

That uncertainty often leads to:

• Over-submission to full board review
• Delays in study initiation
• Higher costs
• Projects being postponed or abandoned

The challenge is not just knowing the categories. It is applying them correctly to your specific study design, data, participants, and risk level.

How to Choose the Right IRB Path Without Guesswork

One of the biggest bottlenecks in the IRB process is not submission. It is figuring out where to start.

The RapidIRB Screening Tool is designed to guide researchers through a structured, regulation-aligned decision process in minutes. Instead of interpreting dense policy language on your own, you answer a series of targeted questions about your study.

The tool helps evaluate questions such as:

• Are you interacting with human subjects?
• Is the data identifiable or de-identified?
• Does the study involve more than minimal risk?
• Is the activity research or quality improvement?

Behind the scenes, the tool maps those responses to Common Rule criteria under 45 CFR 46 to help identify the most appropriate pathway.

What the RapidIRB Screening Tool Helps You Do

1. Determine Whether Your Project Requires IRB Review at All

Not every project meets the definition of human subjects research. The screening process can help clarify whether your work may fall under:

• Quality improvement
• Program evaluation
• Evidence-based practice initiatives

2. Identify Exempt Eligibility Quickly

For low-risk studies, the tool helps assess whether your project aligns with one of the exemption categories, reducing back-and-forth and saving time.

3. Avoid Over-Submission

One of the most common and costly mistakes is submitting a low-risk study for full board review. A structured screening process helps align your study with the least burdensome compliant pathway.

4. Increase Confidence in Your Decision

Instead of relying on interpretation alone, you receive a structured determination that can support:

• Publication requirements
• Organizational compliance
• Grant or funding documentation

A Simple Framework to Narrow Down Your IRB Path

Even before using a screening tool, you can begin narrowing your pathway by asking three key questions.

1. What Is the Level of Risk?

• No more than everyday life risk. Often Exempt or Expedited
• Greater than minimal risk. Often Full Board Review

2. What Type of Data Are You Using?

• De-identified data. Often Exempt
• Identifiable or sensitive data. Often Expedited or Full Board

3. Are You Interacting With Participants?

• No interaction. Often Exempt
• Surveys or interviews. Exempt or Expedited
• Interventions. Expedited or Full Board

Common IRB Mistakes to Avoid

Even experienced researchers can misjudge the right path. Common mistakes include:

• Assuming a study is exempt without formal confirmation
• Submitting to full board review just to be safe
• Confusing quality improvement with research, especially when publication is planned
• Relying only on institutional access that may not fit your timeline or budget

Where RapidIRB Fits In

For many clinicians, healthcare innovators, and independent researchers, the main barrier is not the study itself. It is access to a timely, affordable, compliant IRB pathway.

RapidIRB was built to remove that barrier.

With RapidIRB, you can:

• Use the Screening Tool to determine your correct pathway in minutes
• Receive instant exempt determinations aligned with federal regulations
• Access affordable, compliant review options without institutional dependency
• Generate documentation ready for publication, compliance, or funding

This gives researchers a faster, clearer way to move forward without extended delays or unnecessary expense.

Final Thoughts. Don’t Let IRB Be the Barrier

The purpose of IRB oversight is protection, not prevention.

When you understand the different IRB pathways and use the right decision tools, the process becomes far more manageable and far less intimidating.

Whether you are a nurse leader evaluating practice changes, a clinician conducting a study, or an entrepreneur building something new, there is a clear path forward.

The key is choosing the right one from the start.

References:

• U.S. Department of Health and Human Services. (2018). Federal Policy for the Protection of Human Subjects (‘Common Rule’). 45 CFR 46. 
• Office for Human Research Protections (OHRP). (2020). Exempt Research Determination. U.S. Department of Health and Human Services.
• Grady, C. (2015). Institutional review boards: Purpose and challenges. Chest, 148(5), 1148–1155. 
• Fiske, S. T., & Hauser, R. M. (2014). Protecting human research participants in the age of big data. Proceedings of the National Academy of Sciences, 111(38), 13675–13680.